Levodopa/Carbidopa/Entacapona Stada (Carbidopa, Entacapone, Levodopa)

The combination works by delivering levodopa, a dopamine precursor, to the brain where it is converted to dopamine. Carbidopa blocks peripheral conversion of levodopa, increasing its availability to the central nervous system, while entacapone inhibits the COMT enzyme, prolonging levodopa's plasma half‑life and enhancing overall dopaminergic activity.

Dosage is individualized and determined by the prescribing clinician based on disease severity, patient response, and tolerability. The prescriber will select the appropriate strength and dosing schedule, which may be adjusted over time to achieve optimal symptom control while minimizing side effects.

Safety data in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case carefully before prescribing during pregnancy or while breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Standard levodopa/carbidopa provides dopamine replacement but has a shorter plasma half‑life, leading to more frequent dosing and motor fluctuations. Adding entacapone inhibits COMT metabolism, extending levodopa's duration of action, reducing OFF periods, and often allowing fewer daily doses compared with levodopa/carbidopa alone.

The product should be stored at ambient temperature, preferably below 25 °C, in its original packaging. It must be kept away from excess moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Levodopa/Carbidopa/Entacapone is taken orally as a tablet. Patients should swallow the tablet whole with a full glass of water. It may be taken with or without food, although a high‑protein meal can affect levodopa absorption, so timing relative to meals may be adjusted by the prescriber.

Serious adverse events include hallucinations or psychotic symptoms, severe hypotension that can lead to fainting, neuroleptic malignant syndrome, and dyskinesia that may become disabling. Any of these symptoms require immediate medical evaluation and possible modification of therapy.

Patients with known hypersensitivity to levodopa, carbidopa, entacapone or any excipients should avoid the product. It is also contraindicated in individuals with narrow‑angle glaucoma, severe hepatic impairment, or those taking non‑selective MAO inhibitors. Clinicians must assess each patient's medical history before initiating therapy.